A provider's guide to helping patients afford Zarxio. Learn about copay assistance, patient assistance programs, and cost conversation strategies.
As clinicians, we know that prescribing the right medication is only half the battle. If a patient cannot afford Zarxio (Filgrastim-sndz), they may delay filling their prescription, skip doses, or abandon treatment altogether — with potentially life-threatening consequences.
Zarxio plays a critical role in preventing febrile neutropenia in chemotherapy patients, supporting bone marrow transplant recovery, and managing severe chronic neutropenia. When patients cannot access it due to cost, the clinical consequences are real: increased infection risk, hospitalization, chemotherapy delays, and worse outcomes.
This guide provides a practical framework for helping your patients navigate the financial landscape of Zarxio therapy in 2026.
Understanding the cost landscape helps you anticipate which patients will need financial assistance:
Without insurance, Zarxio costs approximately $250 to $450 per prefilled syringe (480 mcg). A typical chemotherapy cycle requiring 7 to 14 days of daily injections can total $2,500 to $6,000 or more. While Zarxio is significantly less expensive than the reference product Neupogen ($500-$900 per syringe), the cost remains substantial for uninsured patients.
Most commercial plans cover Zarxio, often preferring it over Neupogen as a lower-cost biosimilar. However, specialty medication copays and coinsurance can still range from $50 to $500+ per fill, depending on the plan design. High-deductible health plans can be particularly burdensome at the start of the year.
Medicare Part B covers Zarxio when administered in a clinical setting (incident to a physician service). Patients are responsible for the 20% coinsurance after meeting their Part B deductible. For patients receiving Zarxio at home via self-injection, Part D coverage applies, with costs varying by plan formulary and coverage phase.
Medicaid generally covers Zarxio, though prior authorization requirements and preferred biosimilar status vary by state. Out-of-pocket costs for Medicaid patients are typically minimal.
Sandoz offers the One Source patient support program for Zarxio, which includes:
Contact Sandoz One Source at their dedicated phone line or visit sandoz.com for current program details and eligibility criteria. Note that copay assistance programs are typically not available to patients covered by federal healthcare programs (Medicare, Medicaid, TRICARE).
For patients who are uninsured or underinsured and meet income eligibility requirements, the Novartis Patient Assistance Foundation may provide Zarxio at no cost. This is one of the most impactful resources for your financially vulnerable patients. Applications can be submitted by the prescribing provider on the patient's behalf.
Beyond manufacturer programs, several independent organizations can help patients access Zarxio:
While specialty biologics like Zarxio are less commonly discounted through retail coupon cards compared to oral medications, some options exist:
For a patient-facing overview of savings options, direct patients to our guide to saving money on Zarxio.
As a biosimilar itself, Zarxio already represents a cost-effective alternative to Neupogen. However, understanding the full landscape of G-CSF options can help with formulary navigation:
When a patient's plan does not cover Zarxio or places it on a high cost-sharing tier, consider whether a therapeutic alternative might be covered more favorably. Switching between short-acting Filgrastim products is generally straightforward; switching between short-acting and long-acting G-CSF requires clinical consideration.
Proactive cost discussions improve adherence and patient satisfaction. Here are practical strategies for incorporating financial screening into your practice:
Ideally, financial assessment should happen before the first Zarxio prescription is written. When initiating a G-CSF-requiring chemotherapy regimen, have your team verify insurance coverage, check for prior authorization requirements, and identify potential cost barriers during the treatment planning phase.
Many patients are embarrassed to discuss financial hardship. Normalizing the topic reduces this barrier:
"Zarxio is an important part of your treatment, and I want to make sure cost isn't going to be a problem. Let's talk about what your insurance covers and what options we have to keep your costs manageable."
Assign a financial navigator, social worker, or trained staff member to handle Zarxio access issues. This person should be familiar with:
Track which patients are enrolled in assistance programs and when re-enrollment is needed. Some programs have annual renewal requirements. Set reminders in your EHR or practice management system.
When patients report difficulty finding Zarxio in stock — an increasingly common issue given ongoing supply variability — direct them to Medfinder for Providers to check real-time pharmacy availability. You can also use it within your practice to identify stocking pharmacies before sending a prescription.
For more clinical guidance on managing Zarxio in your practice, see our provider's guide to finding Zarxio in stock and our prescriber shortage update for 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
